Protocol Ledger

NCT05439629 · Phase III · COMPLETED

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Interventional Phase III clinical trial protocol NCT05439629 sponsored by Bio-Thera Solutions in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-07 Enrollment: 488 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05439629
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)488 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05439629
Protocol FieldVerified Registry Value
NCT IdentifierNCT05439629
Consolidated Lead SponsorBio-Thera Solutions
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment488 participants (ACTUAL)
Registered Start Date2022-07-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05439629
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
China-Japan Friendship HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI